In order to assess the potential impact of MDM4 SNP34091 status on cancer risk, we compared the frequency of the MDM4 SNP34091 genotypes among breast‐ (n = 1,717), lung‐ (n = 1,331), colon‐ (n = 1,531), and prostate cancer (n = 2,500) patients to healthy controls (n = 3,747). This evidence concerns the gene MDM4 and prostate cancer.